マサチューセッツ州における悪性黒色腫の臨床試験
マサチューセッツ州内の拠点で、悪性黒色腫に関する29件の研究が参加者を募集しています。
マサチューセッツ州内の都市
公式研究テキスト（英語）
Phase 1/2 Study of Intravenous Injection of STX-003 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab
- Massachusetts General Hospital, Boston
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/10/02更新 · NCT07751042BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
- Baystate Medical Center, Springfield
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/25更新 · NCT05136196Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
- Tufts Medical Center, Boston
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/24更新 · NCT06047379A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
- Local Institution - 0124, Boston
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/16更新 · NCT07492680DOC1021 Dendritic Cell Immunotherapy for Refractory Melanoma
- Massachusetts General Hospital Cancer Institute, Boston
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/09更新 · NCT07288112Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases
- Brigham and Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/09更新 · NCT04899908A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
- Dana Farber Cancer Institute, Boston
- Massachusetts General Hospital, Boston
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/02更新 · NCT07070232Cryoablation+Ipilimumab+Nivolumab in Melanoma
- Massachusetts General Hospital Cancer Center, Boston
被験者募集中第2相
18歳以上 · 全性別 · 2026/08/27更新 · NCT05779423Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
- Dana-Farber Cancer Institute, Boston
被験者募集中第1/2相
12 Months – 30 Years · 全性別 · 2026/08/25更新 · NCT04851119Project: Every Child for Younger Patients With Cancer
- Massachusetts General Hospital Cancer Center, Boston
- Dana-Farber Cancer Institute, Boston
- Baystate Medical Center, Springfield
- 他1件
被験者募集中観察研究
25歳以下 · 全性別 · 2026/08/25更新 · NCT02402244Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors
- Massachusetts General Hospital, Boston
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/08/14更新 · NCT06425926A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
- Massachusetts General Hospital Cancer Center, Boston
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/08/11更新 · NCT05592626A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
被験者募集中第1相
18歳以上 · 全性別 · 2026/07/28更新 · NCT06150664A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
- Call for Information (Investigational Site 0026), Boston
被験者募集中第1/2相
6 Months – 17 Years · 全性別 · 2026/07/06更新 · NCT02332668Integrated Cancer Repository for Cancer Research
- Holyoke Medical Center, Holyoke
被験者募集中観察研究健康なボランティア歓迎
19歳〜110歳 · 全性別 · 2026/06/29更新 · NCT02012699Video Education With Result Dependent dIsclosure
- Dana Farber Cancer Institute, Boston
被験者募集中
18歳以上 · 全性別 · 2026/05/22更新 · NCT05225428Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
- Dana Farber Cancer Institute, Boston
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/05/15更新 · NCT05379985ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors
- Massachusetts General Hospital, Boston
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/05/13更新 · NCT03686124Neoadjuvant Darovasertib in Primary Uveal Melanoma
- Massachusetts General Hospital, Boston
被験者募集中第3相
18歳以上 · 全性別 · 2026/05/06更新 · NCT07015190A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma
- Dana Farber, Boston
被験者募集中第2/3相
18歳以上 · 全性別 · 2026/04/22更新 · NCT06624644A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
- Massachusetts General Hospital, Boston
被験者募集中第2/3相
全年齢 · 全性別 · 2026/04/02更新 · NCT06581406Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)
- Massachusetts General Hospital, Boston
- Beth Israel Deaconess Medical Center (BIDMC), Boston
- Dana Farber Cancer Institute, Boston
被験者募集中第3相
18歳以上 · 全性別 · 2026/02/25更新 · NCT05549297ACTengine® IMA203 Combined With mRNA-4203
- Dana Farber Cancer Institute, Boston
被験者募集中第1相
18歳以上 · 全性別 · 2026/01/08更新 · NCT06946225Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV Melanoma
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
被験者募集中第2相
18歳〜100歳 · 全性別 · 2026/01/05更新 · NCT05428007SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Worcester
被験者募集中観察研究
全年齢 · 全性別 · 2025/10/28更新 · NCT03452774A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
被験者募集中第1/2相
18歳以上 · 全性別 · 2025/10/08更新 · NCT04370587A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
- Massachusetts General Hospital, Boston
被験者募集中第1/2相
18歳以上 · 全性別 · 2025/02/13更新 · NCT05669430Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067
- Massachusetts General Hospital, Boston
被験者募集中第1/2相
18歳以上 · 全性別 · 2024/11/15更新 · NCT04787042Phase II Trial of Neoadjuvant and Adjuvant IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Resectable Tumors
- Dana Farber Cancer Institute, Boston
被験者募集中第2相
18歳以上 · 全性別 · 2024/03/18更新 · NCT05280314ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。